ClinVar Miner

Submissions for variant NM_000350.3(ABCA4):c.4918C>T (p.Arg1640Trp) (rs61751404)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Institute of Human Genetics, Univ. Regensburg,Univ. Regensburg RCV000408519 SCV000281907 likely pathogenic Stargardt disease 1 2016-01-01 criteria provided, single submitter clinical testing
GeneDx RCV000085683 SCV000321353 pathogenic not provided 2018-10-04 criteria provided, single submitter clinical testing The R1640W pathogenic variant in the ABCA4 gene has been reported previously in autosomal recessive Stargardt disease in affected individuals when in the homozgyous state or when in trans with another pathogenic variant (Battu et al., 2015; Fujinami et al., 2013; Rozet et al., 1998). The R1640W variant has been reported on the same allele (in cis) with the W1408R variant in families with Stargardt disease, and in a family presenting with both Stargardt disease and retinitis pigmentosa, when in trans with another pathogenic variant (Valverde et al, 2006; Shroyer et al, 2001). Shroyer et al. (2001) showed very little protein from cells transfected with the W1408R and R1640W variants in cis; however, proteins bearing only the W1408R or the R1640W variants appear to have mild or moderate defects in expression or stability. The R1640W variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R1640W variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species. We interpret R1640W as a pathogenic variant.
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000085683 SCV000339315 other not provided 2017-08-31 criteria provided, single submitter clinical testing
Invitae RCV000085683 SCV001210838 pathogenic not provided 2020-06-24 criteria provided, single submitter clinical testing This sequence change replaces arginine with tryptophan at codon 1640 of the ABCA4 protein (p.Arg1640Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is present in population databases (rs61751404, ExAC 0.001%). This variant has been observed in many individuals affected with ABCA4-related conditions. While this variant is commonly found in cis with the variant p.Trp1408Arg, it has also been observed without p.Trp1408Arg in affected individuals (PMID: 28041643, 28559085, 29925512, 9781034). ClinVar contains an entry for this variant (Variation ID: 99330). This variant has been reported to affect ABCA4 protein function (PMID: 11687513). This variant disrupts the p.Arg1640 amino acid residue in ABCA4. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11527935, 26103963, 23755871, 10711710, 28118664). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Blueprint Genetics RCV000210311 SCV001239246 pathogenic Retinal dystrophy 2019-08-16 criteria provided, single submitter clinical testing
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV000085683 SCV001447306 likely pathogenic not provided 2020-10-23 criteria provided, single submitter clinical testing
Ocular Genomics Institute, Massachusetts Eye and Ear RCV000408519 SCV001573564 pathogenic Stargardt disease 1 2021-04-08 criteria provided, single submitter research The ABCA4 c.4918C>T variant was identified in an individual with retinitis pigmentosa with a presumed recessive inheritance pattern. Through a review of available evidence we were able to apply the following criteria: PM2, PP3, PS3, PM1, PM3-S. Based on this evidence we have classified this variant as Pathogenic.
Retina International RCV000085683 SCV000117823 not provided not provided no assertion provided not provided
Centre for Genomic Medicine, Manchester,Central Manchester University Hospitals RCV000210311 SCV000259103 pathogenic Retinal dystrophy 2015-01-30 no assertion criteria provided clinical testing
NIHR Bioresource Rare Diseases, University of Cambridge RCV000505114 SCV000598986 likely pathogenic Leber congenital amaurosis 2015-01-01 no assertion criteria provided research
Medical Genetics Laboratory, Kennedy Center,Juliane Marie Center, Rigshospitalet RCV000787504 SCV000926470 pathogenic Stargardt disease 2018-04-01 no assertion criteria provided research
Sharon lab,Hadassah-Hebrew University Medical Center RCV000787504 SCV001160839 pathogenic Stargardt disease 2019-06-23 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.